General Information of Drug (ID: DM7OIY8)

Drug Name
C[L-Tyr-D-pro-L-Phe-D-trp] Drug Info
Synonyms CHEMBL506217; c[L-Tyr-D-pro-L-Phe-D-trp]
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44583374
TTD Drug ID
DM7OIY8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Opioid receptor mu (MOP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [2]
Morphine DMRMS0L Advanced cancer 2A00-2F9Z Approved [3]
Hydromorphone DMHP21E Back pain ME84.Z Approved [4]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [5]
Fentanyl DM8WAHT Analgesia MB40.8 Approved [6]
Alfentanil DMVO0UB Anaesthesia 9A78.6 Approved [7]
Naloxegol DML0B41 Opioid-induced constipation DB32.1 Approved [8]
Eluxadoline DMYZ0P1 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [9]
Nalfurafine hcl DMA9DHW Uremic pruritus EC90.10 Approved [10]
Oxycodone DMXLKHV Osteoarthritis FA00-FA05 Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nalbuphine DMOSQGU Pain MG30-MG3Z Approved [12]
Nalfurafine hcl DMA9DHW Uremic pruritus EC90.10 Approved [10]
CHLOROXINE DMFZBMQ Erythema ME64.0 Approved [13]
Difelikefalin DMHZBEO Pruritus EC90 Approved [14]
Dezocine DMJDB0Y Pain MG30-MG3Z Approved [15]
Asimadoline DMND3AB Diarrhea-predominant irritable bowel syndrome DD91.01 Phase 3 [16]
JNJ 67953964 DMJ8Y5N Major depressive disorder 6A70.3 Phase 3 [17]
PHN-131 DM1SV8I Pain MG30-MG3Z Phase 2/3 [18]
CR-845 DMJYTUQ Pain MG30-MG3Z Phase 2/3 [19]
Carfentanil DM7ADGX N. A. N. A. Phase 2 [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor kappa (OPRK1) TTQW87Y OPRK_HUMAN Inhibitor [1]
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Inhibitor [1]

References

1 Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
2 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
3 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
4 Clinical pipeline report, company report or official report of signaturerx.
5 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
6 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
7 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
8 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
9 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
10 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3.
16 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
17 Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. Handb Exp Pharmacol. 2022;271:473-491.
18 Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402.
19 Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322.
20 Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.